ABSTRACT

Introduction: There is a rising global interest in the pharmacoeconomic evaluations of bedaquiline (BDQ), a novel oral diarylquinoline, for treatment of drug-resistant tuberculosis (DR-TB).

Areas covered: This article systematically reviewed publications retrieved from Medline, American Psychological Association-Psychology information, Web of Science, Embase, Scopus, Science direct, Center for Reviews and Dissemination, and CINAHL Complete during 2010–2020 on pharmacoeconomic studies on BDQ for DR-TB treatment. Ten Markov model-based cost-effectiveness analyses identified were conducted in high (n = 4), intermediate (n = 2), and low (n = 4) TB burden countries.

Expert opinion: The paucity of model-based health economic analyses on BDQ-containing regimens for DR-TB indicated that further pharmacoeconomic research of BDQ-based regimens, on the aspects of duration of BDQ treatment, types of DR-TB indicated, and settings of regions and health-systems, is highly warranted to inform global cost-effective use of BDQ-based regimens for DR-TB treatment.

摘要

简介：全球对贝达喹啉 (BDQ)（一种新型口服二芳基喹啉）用于治疗耐药结核病 (DR-TB) 的药物经济学评价越来越感兴趣。

涵盖的领域：本文系统地回顾了从 Medline、美国心理学会-心理学信息、Web of Science、Embase、Scopus、Science direct、审查和传播中心和 CINAHL Complete 2010-2020 年期间检索的关于 BDQ 用于 DR 的药物经济学研究的出版物- 结核病治疗。在高 (n = 4)、中 (n = 2) 和低 (n = 4) 结核病负担国家进行了 10 项基于马尔可夫模型的成本效益分析。

专家意见: 基于模型的 DR-TB 含 BDQ 方案的健康经济学分析的缺乏表明基于 BDQ 的方案的进一步药物经济学研究，在 BDQ 治疗的持续时间、适应症的 DR-TB 类型和设置方面地区和卫生系统，非常有必要为全球经济有效地使用基于 BDQ 的 DR-TB 治疗方案提供信息。